CXCL12 and cancer: A previous study showed that CXCL12 secreted by CAFs limits T cell recruitment into the cancer tissue, and CAF depletion or CXCL12 inhibition leads to T cell accumulation, thereby enhancing the therapeutic effect of ICI in a mouse PDAC model [75].